Trending...
- Free 6-Month Premium Matrimonial Membership Now Available on IndoMarry.com
- Martial Arts Icon Cynthia Rothrock Premieres Her Latest Film Black Creek
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
Working With World-Class Institutions/Collaborators to Provide Novel Treatment Approaches. Stock Symbol: GNPX
AUSTIN, Texas - CuisineWire -- Genprex, Inc. (Stock Symbol: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Cuisine Wire
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
GNPX Video: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Patent Granted in Singapore for GNPX Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
On August 13th GNPX announced that the Singapore Patent Office has granted a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.
More on Cuisine Wire
This GNPX patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. GNPX will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial.
$GNPX Information: www.genprex.com / https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
GNPX Media Contact: Kalyn Dabbs
Email: Media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Cuisine Wire
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
- SureFlow to Showcase AI and Eco-Technology Energy Management Solutions at GITEX 2024
- Smart Merchant Solution goes BLUU to strengthen its position in the Point of Sale (POS) Solutions and Payments Processing Sector
- Local SF Conservatory Pre-College Student Selected to Perform at Carnegie Hall
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
GNPX Video: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Patent Granted in Singapore for GNPX Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
On August 13th GNPX announced that the Singapore Patent Office has granted a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.
More on Cuisine Wire
- Origination of Prince Oak's new alias and reasons of his change — the Eurasian Prince's newest nominal label is "Papa Eurasia"
- Introducing New Ragin' Cajun CHAMPIONSHIP CHILI!
- Anaptyx Selected Top Wireless Internet Service Provider (WISP) 2024
- Bug Busters Celebrates 40 Years in the Pest Control Industry
- National Minority Health Association and Cell-Ed Announce Upcoming Webinar: Empowering Caregivers Through Innovative Training Programs
This GNPX patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. GNPX will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial.
$GNPX Information: www.genprex.com / https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
GNPX Media Contact: Kalyn Dabbs
Email: Media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on Cuisine Wire
- Voices Rising Festival Celebrates Diversity in E. Islip, GRAMMY Governor LACHI performs!
- VSA Officially Receives SOC 2 Approval
- Martial Arts Icon Cynthia Rothrock Premieres Her Latest Film Black Creek
- Vantiva and Harmonic Partner to Offer Service Providers Easy Transition from DOCSIS to Fiber-based PON Technologies
- CCHR Demands Justice for Victims of Psychiatric Fraud and Patient Sexual Abuse
- First World Chronic Cough Day October 15, 2024
- New Frontier Aerospace Closes Seed Round with Pacific Bays Capital
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
- State of Nayarit Named the Official Mexican Tourism Destination of the Vancouver Canucks
- Life Is Gouda Celebrates Grand Opening of Brick-and-Mortar Location at Life Essentials Refillery
- ProtectVirginia Petitions Virginia Dept of Environmental Quality for Cruise Ship Regulations
- GrowHouse Changes Its Name to Yonder All Day Energy
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience
- Healthy Voyager Cafe Vegan & Gluten Free Fresh Grab n Go Meals to Launch at Phoenix Sky Harbor Airp
- Sidow Sobrino's My Amir in the Running for GRAMMY® Nominations
- Old Vines Supper Club presents educational wine dinner series during October